ATOX1 Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• ATOX1 is a crucial 68-amino-acid copper metallochaperone essential for cellular copper homeostasis, transferring Cu(I) to ATP7A/ATP7B for incorporation into cuproenzymes, and also functions as a nuclear copper-dependent transcription factor.
• The protein's structure is characterized by a ferredoxin-like fold with a conserved Cys-X-X-Cys (CXXC) motif at residues 12-15, which directly binds Cu(I) and is critical for its chaperone activity and interaction with target ATPases.
• ATOX1 translocates to the nucleus in response to stimuli like elevated copper, inflammation, or ROS, where it regulates genes involved in cell proliferation (e.g., Cyclin D1), oxidative stress (e.g., SOD3), and angiogenesis (e.g., VEGFR2).
• Dysregulation of ATOX1 is implicated in various pathologies, including Wilson disease (as a modifier gene), cisplatin chemoresistance in cancers (by promoting copper efflux and sequestration), cardiac hypertrophy, and inflammatory neovascularization.
• ATOX1 is classified as a cuproptosis-related gene, with its expression levels influencing cellular sensitivity to copper-induced regulated cell death, impacting cancer prognosis and therapeutic strategies involving copper ionophores or chelators.
• Therapeutic strategies targeting ATOX1 include copper chelators (e.g., D-Penicillamine, Trientine) for Wilson disease and investigational copper ionophores (e.g., Disulfiram, Clioquinol) or ATOX1-specific inhibitors to overcome chemoresistance in cancer.

Executive Summary & Key Metadata

The ATOX1 (Antioxidant Protein 1) gene encodes a small, 68-amino-acid copper metallochaperone that is central to cellular copper homeostasis, redox balance, and copper-dependent signaling. Originally characterized as a cytosolic copper shuttle delivering Cu(I) to the P₁B-type ATPases ATP7A and ATP7B in the trans-Golgi network, ATOX1 has since been recognized as a multifunctional protein with nuclear roles as a copper-dependent transcription factor, a regulator of cell cycle progression, and a modulator of inflammatory and angiogenic signaling. Its dysregulation is increasingly implicated in cancer chemoresistance, cardiovascular pathology, and copper storage disorders.

The gene is highly conserved across eukaryotes, with orthologs identified in Saccharomyces cerevisiae (Atx1), Caenorhabditis elegans (CUC-1), Drosophila melanogaster, zebrafish, and mammals. The human protein is a ferredoxin-fold protein that binds a single copper ion via a conserved Cys-X-X-Cys (CXXC) motif.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Localization and Gene Structure

The human ATOX1 gene is located on the long arm of chromosome 5 at cytogenetic band 5q33.3. The genomic coordinates (GRCh38/hg38) span approximately chr5: 151,742,000–151,755,000 (reverse strand). The gene spans roughly 13 kb of genomic DNA and contains four exons and three introns. The coding sequence is contained within exons 1–4, with the entire open reading frame encoding a 68-amino-acid protein.

The genomic organization was first characterized by Liu et al. (2003), who demonstrated that the human ATOX1 gene contains a TATA-less promoter with multiple GC-rich regions, consistent with a housekeeping gene expression pattern. The promoter region lacks canonical TATA boxes but contains several Sp1 binding sites, which are critical for basal transcription.

1.2 Promoter Architecture and Regulatory Elements

The 5' flanking region of ATOX1 contains multiple putative transcription factor binding sites. Bioinformatics analysis of the promoter region has identified consensus sequences for:

• Sp1 (GC-boxes): Essential for basal transcription in TATA-less promoters
• AP-1 (Activator Protein-1): Mediates responses to oxidative stress and cytokines
• NF-κB: Links inflammatory signaling to copper metabolism
• Metal-responsive elements (MREs): Putative binding sites for MTF-1 (Metal-responsive Transcription Factor-1), although direct regulation by MTF-1 remains controversial
• HIF-1α (Hypoxia-Inducible Factor 1α): Suggests oxygen-dependent regulation

Studies in yellow catfish (Pelteobagrus fulvidraco) have characterized the atox1 promoter and identified conserved transcription factor binding sites, including those for MTF-1, Sp1, and AP-1, indicating evolutionary conservation of regulatory mechanisms.

1.3 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation sequencing (ChIP-seq) data from ENCODE reveal that the ATOX1 locus is associated with active histone marks (H3K27ac, H3K4me1) in multiple cell types, suggesting the presence of enhancer elements within intronic regions and the 3' flanking sequence. The gene is located in a gene-dense region of 5q33.3, with neighboring genes including PFDN1 (Prefoldin Subunit 1) and GABRP (Gamma-Aminobutyric Acid Type A Receptor Pi Subunit).

1.4 Alternative Splicing and Isoforms

The ATOX1 gene produces a single major transcript of approximately 0.8 kb. No functionally validated alternative splicing isoforms have been described in humans. However, the presence of multiple transcription start sites (TSS) has been reported, generating transcripts with different 5' untranslated regions (UTRs) that may affect translational efficiency.

The mouse Atox1 gene shows similar organization, with four exons and three introns, and is localized to a syntenic region on mouse chromosome 11. The canine ATOX1 gene has also been characterized, and five processed pseudogenes have been identified in the dog genome, indicating historical retrotransposition events.

1.5 Pseudogenes and Genomic Duplications

Five canine ATOX1 pseudogenes have been mapped to different chromosomes, suggesting that the gene has undergone retrotransposition during evolution. In humans, no processed pseudogenes have been officially annotated, but the presence of ATOX1-like sequences in other genomic locations has been suggested by sequence homology searches.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Primary Sequence and Domain Boundaries

The human ATOX1 protein is a 68-amino-acid polypeptide with a molecular weight of approximately 7.4 kDa. The amino acid sequence is:

MPKHEFSVDM TCGGCAEAVS RVLNKLGGVK YDIDLPNKKV CIESEHSMDT LLATLKKTGK TVSYLGLE

The protein adopts a ferredoxin-like fold (βαββαβ), consisting of a four-stranded antiparallel β-sheet packed against two α-helices. This fold is shared with other copper chaperones, including the yeast Atx1 and the bacterial CopZ.

2.2 Structural Domains

2.2.1 The CXXC Copper-Binding Motif

The most critical structural feature is the Cys-X-X-Cys (CXXC) motif located at residues Cys12-Cys15 (sequence: C¹²GGC¹⁵). This motif is surface-exposed and constitutes the primary copper(I)-binding site. The two cysteine thiolates coordinate a single Cu(I) ion in a near-linear geometry, with Cu-S distances of approximately 2.2 Å.

The CXXC motif is conserved from bacteria to humans, underscoring its functional importance. In the copper-loaded state, the protein undergoes a conformational change that increases the solvent exposure of a hydrophobic patch near the metal-binding site, facilitating protein-protein interactions with target ATPases.

2.2.2 The Metal-Binding Loop

The metal-binding loop (residues 11–17) connects β-strand 1 to α-helix 1. This loop is flexible in the apo-state but becomes more rigid upon copper binding. Nuclear magnetic resonance (NMR) studies have shown that copper coordination induces chemical shift perturbations throughout the protein, particularly in the loop region and the C-terminal α-helix.

2.2.3 The C-Terminal Helix and Nuclear Localization Signal

The C-terminal α-helix (residues 55–68) contains a putative nuclear localization signal (NLS). Although a canonical basic NLS is not present, the C-terminal region is required for nuclear translocation in response to copper or inflammatory stimuli. Post-translational modifications in this region, including SUMOylation at lysine residues, regulate nuclear accumulation.

2.2.4 The Dimerization Interface

ATOX1 can form homodimers through a domain-swapping mechanism involving the C-terminal helix. Dimerization is copper-dependent and may represent a mechanism for copper storage or buffering in the cytosol. The dimer interface involves hydrophobic residues in the C-terminal region and the β-sheet surface.

2.3 Three-Dimensional Structure

The solution structure of human ATOX1 has been determined by NMR spectroscopy (PDB: 1FEE). The structure reveals:

• β-sheet: Four antiparallel strands (β1: residues 3–8; β2: residues 23–28; β3: residues 38–43; β4: residues 48–53)
• α-helices: Two helices (α1: residues 17–22; α2: residues 55–68)
• Loop regions: The metal-binding loop (residues 9–16) and the β3-β4 hairpin loop

The overall fold is highly stable, with a melting temperature of approximately 70°C in the apo-state, which increases upon copper binding.

2.4 Post-Translational Modifications

2.4.1 SUMOylation

ATOX1 undergoes ROS-dependent SUMOylation at lysine residues, which promotes its nuclear translocation and transcriptional activity. This modification is induced by reactive oxygen species (ROS) and is critical for endothelial inflammatory and angiogenic signaling.

2.4.2 Phosphorylation

Although ATOX1 lacks a canonical kinase domain, phosphorylation at serine/threonine residues has been predicted by phosphoproteomic analyses. The functional significance of these modifications remains to be fully characterized.

2.4.3 Oxidation of Cysteine Residues

The cysteine residues in the CXXC motif are susceptible to oxidation, forming disulfide bonds or sulfenic acid derivatives. This redox sensitivity allows ATOX1 to function as a copper-redox sensor, linking cellular redox state to copper distribution.

2.5 Interactive 3D Visualizer

Interactive 3D Protein Visualizer: Load ATOX1 (PDB: true)

The interactive visualizer allows exploration of the ATOX1 structure, including the CXXC copper-binding motif, the ferredoxin fold, and the C-terminal nuclear localization region. Users can toggle between apo- and copper-bound conformations, highlight conserved residues, and measure atomic distances.

3. Cellular Signaling Pathways & Molecular Function

3.1 Copper Homeostasis and the Chaperone Function

The canonical function of ATOX1 is the cytosolic delivery of copper(I) to the P₁B-type ATPases ATP7A and ATP7B in the trans-Golgi network. The copper transport pathway proceeds as follows:

1. Cellular copper uptake: Copper enters the cell primarily via the high-affinity copper transporter CTR1 (SLC31A1) at the plasma membrane.
2. Cytosolic copper capture: ATOX1 accepts Cu(I) from CTR1 or from glutathione-bound copper pools.
3. Targeted delivery: ATOX1 transfers Cu(I) to the N-terminal metal-binding domains of ATP7A or ATP7B through direct protein-protein interactions.
4. Incorporation into cuproenzymes: ATP7A/ATP7B translocate copper into the secretory pathway, where it is incorporated into cuproenzymes such as lysyl oxidase (LOX), ceruloplasmin, and dopamine-β-hydroxylase.

The interaction between ATOX1 and ATP7B is mediated by the CXXC motifs of both proteins. Mutations in ATOX1 that disrupt this interaction, such as the p.(Gly14Ser) variant, can impair copper delivery and contribute to Wilson disease phenotypes.

3.2 Nuclear Translocation and Transcription Factor Activity

Beyond its cytosolic chaperone role, ATOX1 translocates to the nucleus in response to:

• Elevated copper levels
• Inflammatory cytokines (e.g., TNF-α)
• Reactive oxygen species (ROS)
• Growth factor stimulation

In the nucleus, ATOX1 functions as a copper-dependent transcription factor, binding to specific DNA sequences in the promoters of target genes. Key transcriptional targets include:

• p47phox (NCF1): A subunit of NADPH oxidase, linking ATOX1 to ROS production
• Extracellular superoxide dismutase (SOD3): An antioxidant enzyme
• Cyclin D1 (CCND1): A cell cycle regulator, connecting ATOX1 to proliferation
• VEGF receptor 2 (KDR): Involved in angiogenesis

The DNA-binding activity of ATOX1 is copper-dependent, with copper coordination inducing a conformational change that exposes a DNA-binding surface. The consensus DNA-binding motif for ATOX1 has been identified as a GT-rich sequence, although the precise recognition elements remain under investigation.

3.3 Regulation of Cell Cycle and Proliferation

ATOX1 interacts with cell cycle proteins, particularly components of the anaphase-promoting complex (APC). This interaction suggests a role in mitotic progression and chromosome segregation. ATOX1 also regulates cyclin D1 expression, creating a positive feedback loop that promotes cell proliferation.

In tumor cells with inactivated p53, the ATOX1-cyclin D1 loop becomes critical for survival. p53 functions as a suppressor of ATOX1 expression under genotoxic stress, and loss of p53 leads to ATOX1 upregulation, promoting proliferation and chemoresistance.

3.4 Inflammatory and Angiogenic Signaling

ATOX1 plays a central role in inflammatory neovascularization through both its chaperone and transcription factor functions. The signaling cascade involves:

1. TNF-α stimulation → ROS production → ATOX1 SUMOylation
2. Nuclear translocation of ATOX1
3. Transcriptional activation of p47phox and other inflammatory genes
4. NADPH oxidase activation → further ROS production
5. VEGF signaling → endothelial cell proliferation and migration

ATOX1 also interacts with TRAF4 (TNF Receptor Associated Factor 4), a scaffold protein involved in inflammatory signaling. This interaction enhances NF-κB activation and promotes endothelial inflammation.

3.5 Copper-Dependent Signaling in Steroidogenesis

Recent studies in yak follicular granulosa cells have demonstrated that copper regulates steroid hormone synthesis through a CCS- and ATOX1-dependent MEK1-ERK1/2 pathway. This finding expands the functional repertoire of ATOX1 to endocrine signaling and reproductive physiology.

3.6 Protein-Protein Interaction Network

ATOX1 participates in a complex network of protein-protein interactions, as documented by BioGRID and STRING databases. Key interaction partners include:

3.7 Cuproptosis and Regulated Cell Death

ATOX1 is classified as a cuproptosis-related gene (CRG). Cuproptosis is a recently described form of regulated cell death triggered by copper ionophores, which cause copper accumulation and subsequent aggregation of lipoylated mitochondrial proteins. ATOX1 expression levels influence cellular sensitivity to cuproptosis:

• High ATOX1: Increased copper buffering capacity, reduced cuproptosis sensitivity
• Low ATOX1: Increased susceptibility to copper-induced cell death

This relationship has prognostic implications in cancers, where cuproptosis-related gene signatures including ATOX1 predict patient outcomes.

3.8 Mermaid Diagram: ATOX1 Signaling Pathways

flowchart TD
    A["Extracellular Copper"] -->|"CTR1"| B["Cytosolic Copper"]
    B -->|"GSH/Glutathione"| C{"ATOX1"}
    C -->|"Chaperone Function"| D["ATP7A/ATP7B"]
    D -->|"Golgi Translocation"| E["Cuproenzyme Activation"]
    E --> F["LOX, Ceruloplasmin, DBH"]
    
    C -->|"Nuclear Translocation"| G["Nuclear ATOX1"]
    G -->|"Cu-dependent TF"| H["Target Gene Expression"]
    H --> I["p47phox, Cyclin D1, SOD3, VEGFR2"]
    
    I --> J["Cell Proliferation"]
    I --> K["ROS Production"]
    I --> L["Angiogenesis"]
    
    C -->|"Cuproptosis Regulation"| M["Cuproptosis Sensitivity"]
    
    N["TNF-α/ROS"] -->|"SUMOylation"| C
    O["p53"] -->|"Transcriptional Repression"| C
    P["COMMD1"] -->|"Interaction"| C

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 ATOX1 Mutations in Wilson Disease

Wilson disease (WD) is an autosomal recessive disorder caused by mutations in ATP7B, leading to copper accumulation in the liver and brain. ATOX1 has been investigated as a modifier gene that may influence WD penetrance and severity.

4.1.1 The p.(Gly14Ser) Variant

The p.(Gly14Ser) variant (c.40G>A) is located within the CXXC copper-binding motif (residues 12–15). In-silico analysis predicts that this substitution:

• Disrupts the local conformation of the metal-binding loop
• Alters the electrostatic surface potential
• Reduces the binding affinity for ATP7B
• May impair copper transfer efficiency

This variant has been identified in Wilson disease patients, suggesting a potential modifier effect.

4.1.2 Other Reported Variants

Mutation screening of the four exons of ATOX1 in 63 Wilson disease patients identified several sequence variants, although none were clearly pathogenic. The analysis revealed:

• Intronic polymorphisms: May affect splicing efficiency
• Synonymous variants: No amino acid changes
• Rare missense variants: Low frequency, uncertain significance

A study of Latvian Wilson disease patients found associations between variants in ATOX1 and COMMD1 with disease symptoms, supporting a modifier role. Similarly, mutation screening of ATOX1 and COMMD1 in Indian WD patients identified potential disease-modifying alleles.

4.2 ATOX1 and Cisplatin Resistance

Cisplatin (cDDP) is a platinum-based chemotherapeutic that shares transport mechanisms with copper. ATOX1 expression is a determinant of cisplatin sensitivity.

4.2.1 Mechanism of Resistance

High ATOX1 expression promotes cisplatin resistance through:

1. Increased copper efflux: ATOX1 delivers copper (and cisplatin) to ATP7A/ATP7B, which pump the drug out of the cell
2. Sequestration: ATOX1 may bind cisplatin directly, reducing its availability for DNA damage
3. Transcriptional effects: ATOX1 upregulates survival genes, including cyclin D1

4.2.2 CRISPR-Cas9 Screening Evidence

A genome-wide CRISPR-Cas9 screen in liver cancer cells identified ATOX1 as a critical gene for cisplatin resistance. Knockout of ATOX1 sensitized cells to cisplatin, while overexpression conferred resistance. Targeted inhibitors of ATOX1 were shown to reverse resistance, suggesting a therapeutic strategy.

4.2.3 Clinical Implications

In head and neck squamous cell carcinoma, ATP7B (the ATOX1 target) mediates cisplatin resistance through extracellular vesicle secretion. ATOX1 expression levels may serve as a predictive biomarker for cisplatin response.

4.3 ATOX1 in Cancer Pathogenesis

4.3.1 Diffuse Large B-Cell Lymphoma (DLBCL)

ATOX1 promotes DLBCL proliferation through MAPK signaling by modulating copper transport. High ATOX1 expression correlates with poor prognosis in DLBCL patients.

4.3.2 Liver Cancer

ATOX1 is overexpressed in hepatocellular carcinoma and contributes to cisplatin resistance. The ATOX1-cyclin D1 axis is particularly important in TP53-mutant tumors.

4.3.3 Lung Cancer

Cuproptosis-related gene signatures including ATOX1 have prognostic value in non-small cell lung cancer (NSCLC). LIPT1 regulates ATOX1 expression in NSCLC, linking mitochondrial metabolism to copper homeostasis.

4.3.4 Breast Cancer

ATOX1 facilitates cell migration in breast cancer cells, a process essential for metastasis. The protein also regulates YAP expression, which confers vulnerability to cuproptosis.

4.3.5 Multiple Myeloma

COMMD3 regulates copper metabolism through the ATOX1-ATP7A-LOX axis, promoting multiple myeloma progression. This pathway represents a potential therapeutic target.

4.3.6 Acute Myeloid Leukemia

Copper homeostasis-related gene dysregulation, including ATOX1, has prognostic significance in AML.

4.4 ATOX1 in Cardiovascular Disease

4.4.1 Cardiac Hypertrophy and Heart Failure

Bioinformatics analysis identified ATOX1 as a cuproptosis-related gene involved in cardiac hypertrophy in heart failure. ATOX1 expression is altered in failing hearts, and copper metabolism dysregulation contributes to cardiac remodeling.

4.4.2 Atherosclerosis

ATOX1 promotes inflammatory signaling in endothelial cells, contributing to atherosclerotic plaque instability. Nuclear ATOX1 regulates genes involved in inflammation and oxidative stress.

4.4.3 Wound Healing and Neovascularization

ATOX1 is a key mediator of copper-dependent wound healing and inflammatory neovascularization. Endothelial ATOX1 promotes angiogenesis through both chaperone and transcription factor functions.

4.5 ATOX1 in Neurological Disorders

4.5.1 Neuronal Survival

ATOX1 promotes neuronal survival and is expressed in distinct neuronal subtypes in the brain. The protein protects neurons from oxidative damage.

4.5.2 Alzheimer's Disease

Copper metabolism-related biomarkers, including ATOX1, have been identified in Alzheimer's disease. Abnormal copper distribution in AD brains may involve ATOX1 dysfunction.

4.5.3 Menkes Disease

ATOX1 mutant cells show altered intracellular copper topography, visualized by X-ray fluorescence microscopy. In Menkes disease (ATP7A deficiency), ATOX1 function is disrupted, leading to copper accumulation in the cytosol.

4.6 ATOX1 in Renal and Hepatic Toxicity

4.6.1 Copper-Induced Renal Toxicity

Period1 (PER1) regulates ATOX1 expression and modulates copper-induced renal toxicity. Circadian regulation of ATOX1 may explain diurnal variation in copper toxicity.

4.6.2 Acute Kidney Injury

Cuproptosis-related genes, including ATOX1, are involved in acute kidney injury pathogenesis. Weighted gene co-expression network analysis identified ATOX1 as a key gene in AKI.

4.6.3 Hepatic Copper Toxicosis

In Bedlington terriers with copper toxicosis, ATOX1 expression is altered. COMMD1 deficiency leads to aberrant expression of copper-associated genes, including ATOX1.

4.7 ATOX1 in Other Diseases

4.7.1 Endometriosis

Gene ontology-driven analysis identified ATOX1 dysregulation in endometriosis.

4.7.2 Ulcerative Colitis

Cuproptosis-related genes, including ATOX1, have diagnostic and therapeutic value in active ulcerative colitis.

4.7.3 Pseudoexfoliation Syndrome

Polymorphisms in copper chaperone genes, including ATOX1, are associated with pseudoexfoliation-syndrome-related cataract.

5. Host-Pathogen & Viral Interactions

5.1 Viral Oncoproteins and ATOX1

While direct interactions between viral proteins and ATOX1 have not been extensively characterized, several lines of evidence suggest functional links:

5.1.1 p53-Inactivating Viruses

Many oncogenic viruses (e.g., HPV, HBV) inactivate p53. Since p53 suppresses ATOX1 expression, viral-mediated p53 degradation leads to ATOX1 upregulation. This creates a permissive environment for copper-dependent proliferation and chemoresistance.

5.1.2 Epstein-Barr Virus and Lymphoma

EBV is associated with DLBCL, where ATOX1 promotes proliferation via MAPK signaling. Viral latency proteins may modulate copper metabolism to support B-cell transformation.

5.2 Bacterial Effectors

5.2.1 Helicobacter pylori and Wilson Disease

H. pylori infection can affect copper metabolism and exacerbate Wilson disease symptoms. The bacterial effector CagA may influence host copper homeostasis, although direct ATOX1 interactions remain speculative.

5.2.2 Mycobacterial Infections

Copper is a host defense mechanism against mycobacteria. Macrophages use copper to kill intracellular pathogens, and ATOX1 may modulate this response by regulating copper availability.

5.3 Parasitic Interactions

5.3.1 Plasmodium and Copper Metabolism

Malaria parasites require copper for growth. Host ATOX1 expression may influence parasite survival by regulating copper availability in erythrocytes and hepatocytes.

5.4 Immune Evasion Mechanisms

ATOX1 promotes inflammatory signaling through NF-κB activation. Pathogens that manipulate host inflammatory responses may indirectly affect ATOX1 function. Additionally, ATOX1-mediated ROS production via p47phox may contribute to host defense, and pathogens that suppress ROS production may target this pathway.

5.5 Cuproptosis and Antimicrobial Defense

Cuproptosis represents a host defense mechanism against pathogens. Copper ionophores that induce cuproptosis have antimicrobial activity, and ATOX1 expression levels may influence susceptibility to copper-mediated killing.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 ATOX1 as a Therapeutic Target

The multifunctional nature of ATOX1 makes it an attractive target for therapeutic intervention, particularly in cancer and cardiovascular disease.

6.2 FDA-Approved Drugs Affecting ATOX1 Function

6.2.1 Copper Chelators

These drugs reduce copper availability, indirectly affecting ATOX1 function.

6.2.2 Copper Ionophores

Clioquinol inhibits dopamine-β-hydroxylase secretion and noradrenaline synthesis by affecting the redox status of ATOX1 and copper transport.

6.3 Investigational Small-Molecule Inhibitors

6.3.1 ATOX1-Targeted Inhibitors

CRISPR-Cas9 screening identified ATOX1 as a target for overcoming cisplatin resistance in liver cancer. Targeted inhibitors evaluated in this study showed efficacy in reversing resistance and sensitizing cancer cells to cisplatin.

6.3.2 Copper-Binding Compounds

Selenocysteine-containing analogues of Atx1-based peptides protect cells from copper ion toxicity. These peptides may serve as lead compounds for developing ATOX1 modulators.

6.3.3 DC_AC50 and Other Cuproptosis Inducers

Compounds that induce cuproptosis by increasing copper levels may be more effective in cells with low ATOX1 expression. ATOX1 gene silencing increases susceptibility to anticancer therapy based on copper ionophores or chelating drugs.

6.4 Gene Therapy Approaches

6.4.1 ATOX1 Overexpression

In conditions where ATOX1 function is deficient, gene therapy to overexpress ATOX1 may be beneficial. This approach is theoretical but supported by the protein's role in neuronal survival.

6.4.2 ATOX1 Knockdown

In cancers where ATOX1 promotes proliferation and chemoresistance, RNA interference (siRNA/shRNA) or antisense oligonucleotides targeting ATOX1 may be therapeutic. Preclinical studies have demonstrated that ATOX1 silencing sensitizes cancer cells to chemotherapy.

6.5 Pharmacogenomic Considerations

6.5.1 ATOX1 Polymorphisms and Drug Response

Genetic variants in ATOX1 may influence response to:

• Cisplatin: High ATOX1 expression predicts resistance
• Copper chelators: Variants affecting ATP7B interaction may alter chelation efficacy
• Cuproptosis inducers: Low ATOX1 expression predicts sensitivity

6.5.2 Biomarker Development

ATOX1 expression levels are being evaluated as:

• Prognostic biomarkers in DLBCL, AML, NSCLC, and colon adenocarcinoma
• Predictive biomarkers for cisplatin response
• Diagnostic biomarkers in ulcerative colitis and acute kidney injury

6.6 Drug Repurposing Opportunities

6.6.1 Zinc Supplementation

Perioperative zinc supplementation affects copper circulating levels and expression of metallothionein and ATOX1 in leukocytes. Zinc may modulate ATOX1 expression as a therapeutic strategy.

6.6.2 Nannochloropsis oculata Supplementation

Microalgae supplementation affects gene expression of immune and antioxidant markers, potentially including ATOX1.

6.6.3 Nanoselenium

Nanoselenium alleviates cadmium-induced cerebral injury by regulating metal transporters, potentially including ATOX1.

7. Bioinformatic Resources & Database Accessions

7.1 Gene Ontology (GO) Terms

7.2 Expression Data

ATOX1 is ubiquitously expressed across human tissues, with highest expression in:

• Liver
• Kidney
• Brain (particularly neurons)
• Heart
• Endothelial cells

Single-cell RNA sequencing data from the Human Protein Atlas confirm broad expression with cell-type-specific enrichment in hepatocytes, renal tubular cells, and endothelial cells.

8. Evolutionary Conservation and Model Organisms

8.1 Phylogenetic Distribution

ATOX1 orthologs are present in:

8.2 Model Organism Studies

8.2.1 Mouse Models

• Atox1 knockout mice: Viable but show defects in copper distribution, reduced LOX activity, and impaired wound healing [

Related Clinical & Scientific Guides

• UTY Gene: Structure, Function, and Clinical Significance
• ZBTB42 Gene: Structure, Function, and Clinical Significance
• TTLL8 Gene: Structure, Function, and Clinical Significance